nSTRIDE Therapy
nStride (Autologous Protein Solution, APS) is a biologic injection made from a patient’s own blood, designed to reduce inflammation and relieve pain in mild–moderate knee osteoarthritis by delivering concentrated anti‑inflammatory proteins and growth factors directly into the joint. It aims to slow cartilage breakdown and improve function, offering a non‑surgical option for patients who haven’t responded to conservative treatments.
nStride is an autologous protein solution (APS)—meaning it’s created from your own blood.
The processed solution contains:
High levels of anti‑inflammatory cytokines
White blood cells and platelets
Anabolic growth factors that support cartilage matrix repair
These components work together to counteract inflammatory proteins that drive osteoarthritis progression.
In osteoarthritis, harmful inflammatory cytokines (like IL‑1 and TNF‑α) accelerate cartilage degeneration.
nStride:
Introduces high concentrations of anti‑inflammatory proteins to neutralize these cytokines
May slow cartilage breakdown
May stimulate cartilage repair through growth factors
Targets the underlying inflammatory imbalance in OA rather than just symptoms
This makes it more targeted than platelet‑rich plasma (PRP), which does not specifically concentrate anti‑inflammatory cytokines
nStride is primarily used for:
Mild to moderate knee osteoarthritis
Patients who have not responded to:
Physical therapy
NSAIDs
Corticosteroid injections
Hyaluronic acid injections
It is not recommended for severe OA where cartilage is nearly gone, and it does not replace joint replacement surgery, though it may delay it.
Studies show up to 70% improvement in knee pain at 2 years after a single injection
Laboratory testing shows APS can block and slow cartilage degradation by inhibiting inflammatory proteins
Considerations
Not suitable for advanced OA
Effects may take weeks to appear
As an autologous therapy, risks are generally low, but may include temporary swelling or discomfort